Verve Therapeutics Inc

NASDAQ:VERV   3:59:53 PM EDT
33.35
+0.20 (+0.60%)
Earnings Announcements

Verve Therapeutics Reports Q3 Loss Per Share Of 47 Cents

Published: 11/10/2021 11:50 GMT
Verve Therapeutics Inc (VERV) - Verve Therapeutics Announces Pipeline Progress and Reports Third Quarter 2021 Financial Results.
Q3 Loss per Share $0.47.
Verve-101 Clinical Initiation on Track for 2022.
Revenue is expected to be $0 Million
Adjusted EPS is expected to be -$0.57

Next Quarter Revenue Guidance is expected to be $0 Million
Next Quarter EPS Guidance is expected to be -$0.59

More details on our Analysts Page.